Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606704 | 0.78 | HRH4 (0.57) | HRH4 | |
| SCHEMBL605428 | 0.78 | HRH4 (0.61) | HRH4ADORA2AADORA1HRH3HTR3A | |
| SCHEMBL603633 | 0.78 | HRH4 (0.59) | HRH4HRH3 | |
| Hydrochloric Acid SCHEMBL6512235 | 0.77 | HRH3 (0.63) | HRH4ADORA2AADORA1HRH3HTR3A | |
| SCHEMBL23931315 | 0.76 | HRH4 (0.41) | HRH4HRH3 | |
| SCHEMBL30261044 | 0.76 | HRH4 (0.41) | HRH4HRH3 | |
| SCHEMBL606337 | 0.75 | HRH4 (0.56) | HRH4 | |
| SCHEMBL604007 | 0.73 | HRH4 (0.53) | HRH4 | |
| SCHEMBL21965412 | 0.72 | BPTF (0.48) | HRH4MEN1KMT2AHRH3HTR3A | |
| Hydrochloric Acid SCHEMBL606821 | 0.71 | HRH4 (0.67) | HRH4HRH3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | UCB PHARMA, S.A. (BE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168077-A1 | Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof | CYP4B1, CYP3A4, CYP2C19 | HRH4 240/4885MEN1 1959/4885KMT2A 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.